Cochrane · systematic review · CD007414
Maintenance chemotherapy for ovarian cancer
Mei, L, Chen, H, Wei, DM, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
Gynaecological, Neuro-oncology and Orphan CancerAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
20
current version
GRADE rated
20
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 30%Moderate 14 · 70%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Maintenance chemotherapy versus observation
Population: patients with epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
3‐year PFS Maintenance chemotherapy vs observation | RR 1.07 [0.91, 1.25] | 4 studies · 541 participants | Moderate Downgraded: risk of bias |
5‐year PFS Maintenance chemotherapy vs observation | RR 1.06 [0.97, 1.17] | 3 studies · 761 participants | Moderate Downgraded: risk of bias |
10‐year PFS Maintenance chemotherapy vs observation | RR 0.96 [0.65, 1.41] | 2 studies · 219 participants | Moderate Downgraded: risk of bias |
3‐year OS Maintenance chemotherapy vs observation | RR 1 [0.92, 1.08] | 5 studies · 679 participants | Moderate Downgraded: risk of bias |
5‐year OS Maintenance chemotherapy vs observation | RR 1.03 [0.96, 1.1] | 4 studies · 899 participants | Moderate Downgraded: risk of bias |
10‐year OS Maintenance chemotherapy vs observation | RR 1.08 [0.78, 1.49] | 2 studies · 219 participants | Moderate Downgraded: risk of bias |
Platin‐based maintenance chemotherapy versus observation
Population: patients with epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
3‐year PFS Platin‐based maintenance chemotherapy vs observation | RR 1.04 [0.86, 1.24] | 3 studies · 341 participants | Moderate Downgraded: risk of bias |
5‐year PFS Platin‐based maintenance chemotherapy vs observation | RR 1.18 [0.88, 1.58] | 2 studies · 219 participants | Moderate Downgraded: risk of bias |
10‐year PFS Platin‐based maintenance chemotherapy vs observation | RR 0.96 [0.65, 1.41] | 2 studies · 219 participants | Moderate Downgraded: risk of bias |
3‐year OS Platin‐based maintenance chemotherapy vs observation | RR 1.06 [0.94, 1.18] | 3 studies · 341 participants | Moderate Downgraded: risk of bias |
5‐year OS Platin‐based maintenance chemotherapy vs observation | RR 1.07 [0.88, 1.31] | 2 studies · 219 participants | Moderate Downgraded: risk of bias |
10‐year OS Platin‐based maintenance chemotherapy vs observation | RR 1.08 [0.78, 1.49] | 2 studies · 219 participants | Moderate Downgraded: risk of bias |
Doxorubicin‐based maintenance chemotherapy versus observation
Population: patients with epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
3‐year OS Doxorubicin‐based maintenance chemotherapy vs observation | RR 1 [0.86, 1.15] | 2 studies · 204 participants | Moderate Downgraded: risk of bias |
5‐year OS Doxorubicin‐based maintenance chemotherapy vs observation | RR 1 [0.79, 1.27] | 2 studies · 204 participants | Moderate Downgraded: risk of bias |
Maintenance chemotherapy compared to maintenance radiotherapy for epithelial ovarian cancer
Population: epithelial ovarian cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
3‐year PFS Maintenance chemotherapy vs maintenance radiotherapy | RR 1.07 [0.75, 1.54] | 1 study · 141 participants | Low Downgraded: risk of bias |
5‐year PFS Maintenance chemotherapy vs maintenance radiotherapy | RR 0.86 [0.55, 1.37] | 1 study · 141 participants | Low Downgraded: risk of bias |
10‐year PFS Maintenance chemotherapy vs maintenance radiotherapy | RR 0.89 [0.51, 1.55] | 1 study · 141 participants | Low Downgraded: risk of bias |
3‐year OS Maintenance chemotherapy vs maintenance radiotherapy | RR 1.06 [0.85, 1.32] | 1 study · 141 participants | Low Downgraded: risk of bias |
5‐year OS Maintenance chemotherapy vs maintenance radiotherapy | RR 0.97 [0.7, 1.35] | 1 study · 141 participants | Low Downgraded: risk of bias |
10‐year OS Maintenance chemotherapy vs maintenance radiotherapy | RR 0.94 [0.58, 1.52] | 1 study · 141 participants | Low Downgraded: risk of bias |